ClinicalTrials.Veeva

Menu

Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke

Samsung Medical Center logo

Samsung Medical Center

Status

Unknown

Conditions

Moyamoya Disease
Intracranial Steno-occlusive Disease
Intracranial Atherosclerotic Stroke

Study type

Observational

Funder types

Other

Identifiers

NCT02074111
2013-08-098-003

Details and patient eligibility

About

The aim of this study is to investigate the proportion of patients with moyamoya disease among the patients who were diagnosed as having intracranial atherosclerotic stroke. To do this, biomarkers (gene and imaging) for moyamoya disease are tested and follow up angiography are performed during follow up (in selected patients).

Full description

  1. Purpose Both moyamoya disease (MMD) and intracranial atherosclerotic stenosis (ICAS) are more prevalent in Asians than in Westerners, although the reason for the race-ethnic differences is unsettled. It is possible that patients with adult-onset MMD were misclassified as having ICAS, which may in part explain the high prevalence of intracranial atherosclerosis in Asians. It is important to differentiation between these two diseases because MMD and ICAS have differential therapeutic strategies (surgical revascularization in MMD vs. the use of antithrombotics/statins and stenting in ICAS). The ring finger 213 (RNF213) was recently identified as a susceptibility gene for MMD in East Asians. Characteristic high-resolution (HR) MRI findings of MMD and ICAS have recently been reported. The aim of this study is to investigate the proportion of patients with moyamoya disease among the patients who were diagnosed as having intracranial atherosclerotic stroke. To do this, biomarkers (gene and imaging) for moyamoya disease are tested and follow up angiography are performed during follow up (in selected patients).
  2. Conditions: Stroke, intracranial occlusive lesion
  3. Intervention: None
  4. Study period: Jan 22, 2014 ~ Dec 31, 2016
  5. Study design: Observational model Time perspective: Retrospective-Prospective

Enrollment

400 estimated patients

Sex

All

Ages

20+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Intracranial atherosclerotic stroke

    • Patients with age over 20 years
    • Patients with focal neurological deficits presented within 7 days of symptom onset
    • Patients with acute ischemic lesions on diffusion-weighted image (DWI)
    • Patients with stenosis on the relevant intracranial vessels (distal ICA and/ or M1)
  2. Moyamoya disease

    • Patients with age over 20 years
    • Patients who performed conventional angiography
    • Patients who are diagnosed as having either definite or probable Moyamoya disease
  3. Healthy subjects

    • Subjects with age over 20 years
    • Subjects with no history of cerebrovascular disease

Exclusion criteria

  • Patients with extracranial stenosis more than 50%
  • Patients with potential sources of cardio-aortic embolism
  • Patients with moderate to severe renal disease
  • Pregnancy or lactation
  • Patients with short life expectancy

Trial design

400 participants in 3 patient groups

Intracranial atherosclerotic stroke
Moyamoya disease
Healthy controls

Trial contacts and locations

1

Loading...

Central trial contact

Oh Young Bang, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems